A multicentre non-blinded randomised controlled trial to assess the impact of regular early specialist symptom control treatment on quality of life in malignant mesothelioma (RESPECT-MESO): Study protocol for a randomised controlled trial

A multicentre non-blinded randomised controlled trial to assess the impact of regular early specialist symptom control treatment on quality of life in malignant mesothelioma (RESPECT-MESO): Study protocol for a randomised controlled trial

Background: Malignant pleural mesothelioma is an incurable cancer caused by exposure to asbestos. The United Kingdom has the highest death rate from mesothelioma in the world and this figure is increasing. Median survival is 8 to 12 months, and most patients have symptoms at diagnosis. The fittest p...

Full description

Bibliographic Details
Main Authors: Gunatilake, S., Brims, Fraser, Fogg, C., Lawrie, I., Maskell, N., Forbes, K., Rahman, N., Morris, S., Ogollah, R., Gerry, S., Peake, M., Darlison, L., Chauhan, A.
Format: Journal Article
Published: BioMed Central 2014
Online Access:http://hdl.handle.net/20.500.11937/15278

Internet

http://hdl.handle.net/20.500.11937/15278

Similar Items